Project Grant R01CA289410
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$631K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research program) provides $701,538 to the Icahn School of Medicine at Mount Sinai to investigate the epigenomic drivers and lineage evolution of a novel small cell lung cancer (SCLC) subtype characterized by the NKX2-1 transcription factor. The research aims to: 1) determine how cell-of-origin and NKX2-1 impact the evolution and maintenance of this SCLC epigenomic state, 2) elucidate...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410 to New York University School of Medicine to conduct research aimed at understanding the molecular mechanisms underlying the adeno-to-squamous transition observed in non-small cell lung cancer patients treated with KRAS inhibitors. The key objectives are to: Identify chromatin regulators that drive the adeno-to-squamous transition through a perturbation screen, and then...
This $642,429 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to understand the mechanisms driving cross-resistance in small cell lung cancer (SCLC). The primary grantee, the University of Texas Southwestern Medical Center, is developing and analyzing a panel of 72 patient-derived SCLC xenograft models to investigate how genetic alterations, particularly MYC amplifications on extrachromosomal DNA, contribute to broad drug...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will fund research to investigate the mechanisms underlying lung cancer cell plasticity, both cell-autonomous and non-cell-autonomous. The principal investigator will leverage an innovative evolving lineage tracing model to quantitatively track cancer cell state transitions within the native tumor microenvironment. Specific aims include delineating cell-autonomous regulators of cancer...
This $216,972 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Temple University aimed at understanding and targeting vulnerabilities in small cell lung cancer (SCLC). The key objectives are to: Determine the mechanistic underpinnings of increased replication stress in SCLC, including the role of low LMNA (a nuclear structural protein) and R-loops (RNA-DNA hybrids). This research will inform new therapeutic approaches targeting...
This $3,787,956 federal Project Grant award, issued by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), is funding a multi-year research program at New York University School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The program aims to understand how the SLFN11 gene and replication stress response pathways regulate chemosensitivity in SCLC subtypes, and to develop strategies to combat acquired...
The University of Chicago was awarded a $230,010 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The grant, titled "Unraveling Metastasis Drivers in Small Cell Lung Cancer via Human Pluripotent Stem Cell-Based Approach," aims to leverage the university's recently developed method to generate pulmonary neuroendocrine cells from human pluripotent stem cells. These cells can be transformed to closely...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The $256,487 grant, effective August 13, 2024, supports a 5-year research project to develop multimodal predictive models for non-small cell lung cancer (NSCLC) using real-world data sources such as circulating tumor DNA sequencing, tumor genomics, and clinician notes. The goal is to improve risk stratification and clinical...
This federal Project Grant award from the National Institutes of Health's National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $730,400.00 in funding to the Sloan-Kettering Institute for Cancer Research to conduct research on understanding the metabolic mechanisms that drive the emergence and maintenance of treatment-resistant lung adenocarcinoma (LUAD) cell states. The researchers will use mouse models and patient-derived xenograft models to manipulate components of the...